IL326294A - הרכבי אפילימוד ושיטות לשימוש - Google Patents

הרכבי אפילימוד ושיטות לשימוש

Info

Publication number
IL326294A
IL326294A IL326294A IL32629426A IL326294A IL 326294 A IL326294 A IL 326294A IL 326294 A IL326294 A IL 326294A IL 32629426 A IL32629426 A IL 32629426A IL 326294 A IL326294 A IL 326294A
Authority
IL
Israel
Prior art keywords
methods
apilimod
compositions
apilimod compositions
Prior art date
Application number
IL326294A
Other languages
English (en)
Original Assignee
Orphai Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US18/230,099 external-priority patent/US12589097B2/en
Application filed by Orphai Therapeutics Inc filed Critical Orphai Therapeutics Inc
Publication of IL326294A publication Critical patent/IL326294A/he

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/41521,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/428Thiazoles condensed with carbocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
IL326294A 2023-08-03 2024-08-01 הרכבי אפילימוד ושיטות לשימוש IL326294A (he)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18/230,099 US12589097B2 (en) 2018-02-21 2023-08-03 Apilimod compositions and methods of use
PCT/US2024/040574 WO2025030033A1 (en) 2023-08-03 2024-08-01 Apilimod compositions and methods of use

Publications (1)

Publication Number Publication Date
IL326294A true IL326294A (he) 2026-04-01

Family

ID=94396049

Family Applications (1)

Application Number Title Priority Date Filing Date
IL326294A IL326294A (he) 2023-08-03 2024-08-01 הרכבי אפילימוד ושיטות לשימוש

Country Status (5)

Country Link
KR (1) KR20260048558A (he)
CN (1) CN121666238A (he)
AU (1) AU2024316559A1 (he)
IL (1) IL326294A (he)
WO (1) WO2025030033A1 (he)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10758545B2 (en) * 2015-06-25 2020-09-01 University Of Southern California Methods to treat neurological diseases
AU2019223014B2 (en) * 2018-02-21 2024-10-17 Orphai Therapeutics Inc. Combination therapy with apilimod and glutamatergic agents
EP4351585A1 (en) * 2021-06-11 2024-04-17 Orphai Therapeutics Inc. Stabilized apilimod compositions and uses thereof

Also Published As

Publication number Publication date
CN121666238A (zh) 2026-03-13
KR20260048558A (ko) 2026-04-10
AU2024316559A1 (en) 2026-02-26
WO2025030033A1 (en) 2025-02-06

Similar Documents

Publication Publication Date Title
IL309073A (he) תרכובות אנטקטוגן אננטיומריים ושיטות לשימושן.
IL308041A (he) הרכבי קולגן ושיטות לשימוש בהם
PT4267105T (pt) Composições de anticorpos e métodos de utilização das mesmas
GB2622995B (en) CAS13-based compositions and methods of use thereof
IL312928A (he) תכשירים מאפננים פקטור משלים b ושיטות לשימוש בהם
EP4204004A4 (en) ANTI-IDIOTYPE COMPOSITIONS AND METHODS OF USE
IL316049A (he) תכשירי רוקחות של מוסונטוזומאב ושיטות לשימוש
EP4381022A4 (en) COMPOSITIONS AND METHODS OF USE THEREOF
IL315862A (he) תכשירים מאפננים אנגיוטנסינוגן ושיטות לשימוש בהם
EP4298076A4 (en) CERAMIC COMPOSITIONS AND METHODS OF USE
IL314226A (he) הרכבי ציטוקינים מתוכננים ושיטות לשימוש
IL325628A (he) תכשירים המאפננים פקטור קרישה xi ושיטות לשימוש בהם
IL321134A (he) תרכובות של אולנזפין ושיטות שימוש
IL325816A (he) הרכבי אנדוקסיפן ושיטות לשימוש בהם וסינתיזה שלהם
IL326294A (he) הרכבי אפילימוד ושיטות לשימוש
GB202313643D0 (en) Serping1-sarna compositions and methods of use
GB202310868D0 (en) compositions and methods of use
IL325884A (he) תכשירים הכוללים gal475 ושיטות לשימוש בם
IL311518A (he) תכשירים מאפננים פרקליקריין ושיטות לשימוש בהם
CA3298683A1 (en) Apilimod compositions and methods of use
CA3292256A1 (en) Sleep-improving compositions and methods of use
GB202318443D0 (en) Compositions and methods of treatment
CA3298694A1 (en) Gal475 compositions and methods of use thereof
GB202405768D0 (en) Compositions and uses of oligo-chromopeptides and methods of making
CA3296452A1 (en) Lrrk2-modulating compositions and methods of use thereof